Abstract: A process for the preparation of an amylase inhibitor is disclosed which comprises the steps of:(a) extracting wheat, wheat flour or wheat gluten with water, a dilute acid, a dilute alkali or an aqueous alcohol to produce a solution containing the amylase inhibitor;(b) adding a polysaccharide to said solution to form an insoluble complex of the amylase inhibitor with the polysaccharide and separating the insoluble complex from the solution;(c) dissolving or dispersing said complex in a solution, then separating the polysaccharide from the solution to collect a solution containing the amylase inhibitor; and(d) treating the collected solution with a cation exchanger to recover the amylase inhibitor from fractions that have not been adsorbed on the cation exchanger.

Abstract: A novel melanin formation-inhibitory protein, which has a molecular weight of 90,000.+-.20,000 and a pI of 5.5.+-.0.5, exerts a tyrosinase formation-inhibitory activity in pigment cells but does not substantially inhibit the inherent tyrosinase activity. Thus, the protein is advantageously used as a pharmaceutical and as a cosmetic in the prevention and/or treatment for local chromatosises such as chloasma, ephelis and sunburn, as well as for systemic chromatosises such as addisonism.

Abstract: A method for purifying Interleukin-10 (Il-10) from a eukaryotic cell culture medium. The method is comprised of subjecting IL-10 containing cell culture medium to cation exchange chromatography, anion exchange chromatography, hydroxyapatite chromatography, and gel filtration chromatography. The present invention is also comprised of a process for separating different IL-10 dimers present in a protein fraction from each other by subjecting the protein fraction to hydroxyapatite chromatography. The present invention is also comprised of a process for separating variants of a protein differing in an N-terminal amino acid sequence present in a protein fraction from each other by subjecting the protein fraction to hydroxyapatite chromatography.

Abstract: Herein described is an ovarian cancer activating factor that has been isolated from ovarian cancer ascites fluid. The factor may be utilized in its isolated form in a screening program aimed at identifying inhibitors of factor-mediated ovarian cancer activation, or as a growth supplement useful for culturing ovarian and other cancer cell lines.

Abstract: The invention is directed to a method for the separation of gamma globulin from albumin contained in an aqueous solution of both having a pH of 8-10 by ultrafiltration using an altered substrate microfilter having a water permeability of no more than 20 gallons per square foot per day per pound per square inch.